Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bugat

Showing results (51-60 of 149) with videos related to

Pageof 15
Sort By:
Gastroenterology|December 1, 1976
Detection of a circulating gastric secretagogue in plasma extracts from normogastrinemic patients with acid hypersecretionR Bugat, J H Walsh, A Ippoliti, et al.
Bulletin Du Cancer|January 1, 1990
[Role and results of radiotherapy in the treatment of pancreatic adenocarcinoma]N J Daly, F Izar, R Bugat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluationS Guichard, A Montazeri, E Chatelut, et al.
Cancer Chemotherapy and Pharmacology|July 8, 1998
Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in miceS Guichard, E Chatelut, I Lochon, et al.
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris|March 18, 1982
[Primary tumors of the renal pelvis and ureter: value of postoperative external radiotherapy (author's transl)]T D Nguyen, D Franck, R Bugat, et al.
Frontiers of Gastrointestinal Research|January 1, 1979
Non-Hodgkin's primary lymphomas of the gastrointestinal tract: clinicopathologic correlationR Bugat, J J Voigt, G Delsol, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinomaP Canal, R Bugat, C Michel, et al.
European Journal of Cancer & Clinical Oncology|July 1, 1984
Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathyB Boneu, R Bugat, A Boneu, et al.
Journal of Pharmaceutical Sciences|May 1, 1989
A pharmacokinetic model for intraperitoneal administration of drugs: application to teniposide in humansP Canal, Y Plusquellec, E Chatelut, et al.
Bulletin Du Cancer|January 1, 1989
[Phase I trial and pharmacokinetics of VM 26 combined with cisplatin administered by the intraperitoneal route without mixing time]E Chatelut, P Canal, M De Forni, et al.
Pageof 15

Showing results (51-60 of 149) with videos related to

Sort By:
Pageof 15
Gastroenterology|December 1, 1976
Detection of a circulating gastric secretagogue in plasma extracts from normogastrinemic patients with acid hypersecretionR Bugat, J H Walsh, A Ippoliti, et al.
Bulletin Du Cancer|January 1, 1990
[Role and results of radiotherapy in the treatment of pancreatic adenocarcinoma]N J Daly, F Izar, R Bugat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluationS Guichard, A Montazeri, E Chatelut, et al.
Cancer Chemotherapy and Pharmacology|July 8, 1998
Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in miceS Guichard, E Chatelut, I Lochon, et al.
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris|March 18, 1982
[Primary tumors of the renal pelvis and ureter: value of postoperative external radiotherapy (author's transl)]T D Nguyen, D Franck, R Bugat, et al.
Frontiers of Gastrointestinal Research|January 1, 1979
Non-Hodgkin's primary lymphomas of the gastrointestinal tract: clinicopathologic correlationR Bugat, J J Voigt, G Delsol, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinomaP Canal, R Bugat, C Michel, et al.
European Journal of Cancer & Clinical Oncology|July 1, 1984
Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathyB Boneu, R Bugat, A Boneu, et al.
Journal of Pharmaceutical Sciences|May 1, 1989
A pharmacokinetic model for intraperitoneal administration of drugs: application to teniposide in humansP Canal, Y Plusquellec, E Chatelut, et al.
Bulletin Du Cancer|January 1, 1989
[Phase I trial and pharmacokinetics of VM 26 combined with cisplatin administered by the intraperitoneal route without mixing time]E Chatelut, P Canal, M De Forni, et al.
Pageof 15